A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
Latest Information Update: 02 Apr 2026
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms OPERA
- Sponsors Daehwa Pharmaceutical
Most Recent Events
- 30 Mar 2026 Primary endpoint has not been met. (Objective Response Rate(ORR))
- 30 Mar 2026 Results published in the Breast Cancer Research and Treatment
- 13 Oct 2022 Status has been changed to completed, as per results presented at the 47th European Society for Medical Oncology Congress